| __timestamp | Eli Lilly and Company | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4932500000 | 2043000 |
| Thursday, January 1, 2015 | 5037200000 | 3895000 |
| Friday, January 1, 2016 | 5654900000 | 6552000 |
| Sunday, January 1, 2017 | 6070200000 | 15066000 |
| Monday, January 1, 2018 | 4681700000 | 26348000 |
| Tuesday, January 1, 2019 | 4721200000 | 33097000 |
| Wednesday, January 1, 2020 | 5483300000 | 36272000 |
| Friday, January 1, 2021 | 7312800000 | 52873000 |
| Saturday, January 1, 2022 | 6629800000 | 57909000 |
| Sunday, January 1, 2023 | 7082200000 | 72547000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for assessing a company's financial health. Eli Lilly and Company, a stalwart in the sector, has seen its cost of revenue grow by approximately 44% from 2014 to 2023. In contrast, Exelixis, Inc., a smaller player, experienced a staggering increase of over 3,400% in the same period. This dramatic rise reflects Exelixis's aggressive expansion and investment in research and development.
These trends underscore the differing strategies of established giants and emerging innovators in the pharmaceutical landscape.
Analyzing Cost of Revenue: Eli Lilly and Company and GSK plc
Cost of Revenue: Key Insights for Eli Lilly and Company and BeiGene, Ltd.
Eli Lilly and Company vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Eli Lilly and Company and Bausch Health Companies Inc.'s Expenses
Biogen Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Incyte Corporation and Exelixis, Inc.
Cost of Revenue Comparison: Viatris Inc. vs Exelixis, Inc.
Bio-Techne Corporation vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Amneal Pharmaceuticals, Inc.
Exelixis, Inc. vs Xenon Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Exelixis, Inc. vs Geron Corporation
Exelixis, Inc. vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored